Finally, we point out the development prospects and current challenges in the field of nanomedicines-mediated ADO pathway inhibition, aiming to further promote the clinical translation of ADO pathway inhibitors and enrich the clinical treatment options of tumor immunotherapy. Here, ADO is linked to neoplasm.